Tests shorter radiotherapy after surgery for endometrial cancer
Tests a shorter course of pelvic radiation in women with endometrial cancer after surgery.
Plain-language title generated from the registry record
Registry title: Postoperative Hypofractionated Intensity-modulated Radiotherapy Endometrial Cancer
Key facts
- Where
- Seoul, South KoreaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 20 to 80 who had surgery for stage III endometrioid endometrial cancer and need radiotherapy to the pelvis.
- Age
- 20 to 80 years
- Sex
- Women only
- Disease stage
- Endometrioid type endometrial cancer, confirmed by tissue tests, FIGO stage III, after hysterectomy and surgical staging.
- Earlier treatment
- Must have had a hysterectomy and surgical staging. Chemotherapy after surgery must be done or planned. No earlier radiotherapy to the pelvis.
Main reasons for not taking part
- Cancer has spread to distant parts of the body
- Earlier radiotherapy to the pelvis
- Severe and unstable medical condition
- Another cancer in the past, except thyroid cancer, skin cancer and endometrial cancer
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 80 years old?
Source: NCT05876130, who can take part
Where in South Korea
- Samsung Medical CenterSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Samsung Medical Center
- Trial code
- NCT05876130
- Record updated
- 12 June 2024
- Original description
To investigate the non-inferiority of disease-free survival in women who received hypofractionated intensity-modulated whole pelvic radiation therapy (2.5 Gy x 16 fractions) after curative surgery for stage III endometrial cancer.Read full original descriptionShow less
Postoperative Hypofractionated Intensity-modulated Radiotherapy Endometrial Cancer: A Prospective Phase II Trial (POHIM_EM Trial)
To investigate the non-inferiority of disease-free survival in women who received hypofractionated intensity-modulated whole pelvic radiation therapy (2.5 Gy x 16 fractions) after curative surgery for stage III endometrial cancer.
Inclusion: histologically confirmed endometrioid type endometrial cancer; completion of hysterectomy and surgical staging; pathologically confirmed FIGO stage III; ECOG performance status 0 or 1; adjuvant chemotherapy was done or planned.
Exclusion: previous history of pelvic radiotherapy; previous history of other carcinoma except for thyroid cancer, skin cancer, and endometrial cancer; severe and unstable medical condition; presence of distant metastasis.